Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333288 | 0.90 | CKS1B (0.53) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL28981154 | 0.86 | CKS1B (0.51) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24195984 | 0.85 | MAP4K4 (0.51) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL16333732 | 0.82 | CKS1B (0.52) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL20046337 | 0.81 | GPR119 (0.48) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL20046342 | 0.80 | RET (0.53) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL1873796 | 0.80 | CKS1B (0.57) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL24125575 | 0.80 | MAPT (0.47) | GPR119 | |
| SCHEMBL18163269 | 0.79 | MAP4K4 (0.54) | GPR119CKS1BSKP1SKP2MAP4K4 | |
| SCHEMBL30893577 | 0.79 | DDB1 (0.57) | GPR119CKS1BSKP1SKP2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | GPR119 3864/4885CKS1B 707/4885SKP1 1378/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | GPR119 3864/4885CKS1B 707/4885SKP1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.